



17th UC SAN DIEGO MOORES CANCER CENTER

INDUSTRY/ACADEMIA NEXT GENERATION PRECISION ONCOLOGY SYMPOSIUM

SEPTEMBER 30, 2021 | 8AM - 6PM
LA JOLLA, CALIFORNIA

8:45-9:00

Opening Remarks

Ida Deichaite, PhD, *Moore's Cancer Center, Radiation Medicine & Applied Sciences, UC San Diego*
David Brenner, MD, *Vice Chancellor, Health Sciences, UC San Diego*

Session: Immuno-Oncology

Chair: Ezra Cohen, MD, FRCPSC, FASCO, *Hematology/Oncology, Moore's Cancer Center, UC San Diego*

9:00-9:15

Personalized NeoAg Vaccines

Aaron Miller, MD, PhD, *Precision Immunotherapy Clinic, UC San Diego*

9:15-9:30

Latest Observations of iPSC-derived, Multiplexed Engineered CAR NK and T-Cell Products Targeting Hematological and Solid Tumors

Bob Valamehr, PhD, MBA, *Chief Research and Development Officer, Fate Therapeutics*

9:30-9:45

Chromosome 9p loss drives immune evasion and checkpoint-inhibitor resistance

Scott Lippman, MD, *Director, Moore's Cancer Center, UC San Diego*

9:45-10:00 Session Q&A and Discussion

10:00-10:30

Harnessing RNA for Oncology Drug Development

Robert Hollingsworth, PhD, VP and CSO, *Cancer Vaccines and Immunotherapeutics, Pfizer*

10:30-10:45 Break

10:45-11:00

Duane Roth Award Presentation

Recipient Dennis Carson, MD, *Director Emeritus, Moore's Cancer Center, UC San Diego*

11:00-11:30

Keynote Presentation: Duane Roth Award Lecture

Adventures in Nucleotide Therapeutics

Dennis Carson, MD, *Director Emeritus, Moore's Cancer Center, UC San Diego*

11:30-12:15

Keynote Presentation

Creating and implementing breakthrough technologies: from lab bench to biotech companies

Robert Langer, ScD, *Institute Professor, Chemical Engineering, MIT*

12:15-1:30 Lunch

Session: Solid Tumors

Chair: J. Silvio Gutkind, PhD, *Pathology, Moore's Cancer Center, UC San Diego*

1:30-1:45

Tumor Draining Lymph Nodes: Guardians for Immune-Oncology Therapeutic Response

Robert Saddawi-Konefka, MD, PhD, *Division of Otolaryngology, Department of Surgery, UC San Diego*

1:45-2:00

Targeting small ubiquitin-like modifications to induce anti-tumor immunity

Yuan Chen, PhD, *Division of Surgical Sciences, Department of Surgery, Moore's Cancer Center, UC San Diego*

2:00-2:15

INBRX-106: A novel hexavalent anti-OX40 agonist for the treatment of solid tumors

Emily Rowell, PhD, *Director of Translational Research, Inhibrx*

2:15-2:30

The complex role of KRAS mutations in the pathogenesis of colon cancer and opportunities for targeting the KRAS signaling network for therapeutic intervention

James Christensen, PhD, *CSO and EVP Research, Mirati Therapeutics*

2:30-2:45

Finally, CAR-T success against solid tumors. What's next?

Eric Ostertag, MD, PhD, *Chief Executive Officer, Poseida Therapeutics*

2:45-3:00

Novel Biomarker Strategies in Cancer: From Bench to Bedside and Beyond

Sandip Patel, MD, *Clinical Trials Office, Moore's Cancer Center, UC San Diego*

3:00-3:15 Session Q&A and Discussion

3:15-3:30 Break

Session: Hematology/Oncology

Chair: Thomas Kipps, MD, PhD, *Center for Novel Therapeutics, UC San Diego*

3:30-3:45

Development of a Selective Menin-MLL Inhibitor for Treatment of Acute Leukemias

Troy Wilson, PhD, JD, *President and Chief Executive Officer, Kura Oncology*

3:45-4:00

BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

Caitlin Costello, MD, *Division of Blood and Marrow Transplantation, UC San Diego*

4:00-4:15

Major Mechanisms of CAR-T Cell Treatment Resistance and Future Directions

Mike Mattie, PhD, *Director, Translational Medicine, Kite, a Gilead Company*

4:15-4:30

Rebecsinib

Catriona Jamieson, MD, PhD, *Division of Regenerative Medicine, Moore's Cancer Center, UC San Diego*

4:30-4:45 Session Q&A and Discussion

4:45-5:15

Fireside Chat

John Reed, MD, PhD, *EVP, Global Head of Research and Development, Sanofi*

Thomas Kipps, MD, PhD, *Center for Novel Therapeutics, UC San Diego*

Moderator: Ian Stone, *Canale Communications*